Addex Therapeutics Ltd

1.10-0.0400-3.51%Vol 45.25K1Y Perf -88.87%
Jun 24th, 2022 15:59 DELAYED
BID1.10 ASK1.15
Open1.13 Previous Close1.14
Pre-Market- After-Market1.19
 - -  0.09 8.18%
Target Price
15.00 
Analyst Rating
Strong Buy 1.00
Potential %
1.26K 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★+     52.51
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★+     48.00
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
0.51 
Earnings Rating
Market Cap6.95M 
Earnings Date
4th Aug 2022
Alpha-0.04 Standard Deviation0.19
Beta1.60 

Today's Price Range

1.051.18

52W Range

1.0510.90

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-26.67%
1 Month
-70.27%
3 Months
-78.22%
6 Months
-83.41%
1 Year
-88.87%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ADXN1.10-0.0400-3.51
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
3.90
4.30
0.01
0.03
-178.10
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
-
-798.20
-783.20
-
-
RevenueValueIndustryS&P 500US Markets
2.56M
0.41
-17.95
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.52-0.97-86.54
Q04 2021-0.66-0.83-25.76
Q03 2021-0.72-0.720.00
Q02 2021-0.65-0.77-18.46
Q01 2021-0.65-0.5318.46
Q03 2020--0.78-
Q02 2020--0.75-
Q01 2020--0.99-
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date4th Aug 2022
Estimated EPS Next Report-0.49
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume45.25K
Shares Outstanding6.31K
Shares Float6.31M
Trades Count240
Dollar Volume51.60K
Avg. Volume133.67K
Avg. Weekly Volume310.29K
Avg. Monthly Volume65.31K
Avg. Quarterly Volume25.41K

Addex Therapeutics Ltd (NASDAQ: ADXN) stock closed at 1.1 per share at the end of the most recent trading day (a -3.51% change compared to the prior day closing price) with a volume of 45.25K shares and market capitalization of 6.95M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 27 people. Addex Therapeutics Ltd CEO is Tim Dyer.

The one-year performance of Addex Therapeutics Ltd stock is -88.87%, while year-to-date (YTD) performance is -82.51%. ADXN stock has a five-year performance of %. Its 52-week range is between 1.05 and 10.9, which gives ADXN stock a 52-week price range ratio of 0.51%

Addex Therapeutics Ltd currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 0.73, a price-to-sale (PS) ratio of 3.70, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -84.32%, a ROC of -103.65% and a ROE of -111.66%. The company’s profit margin is -%, its EBITDA margin is -783.20%, and its revenue ttm is $2.56 Million , which makes it $0.41 revenue per share.

Of the last four earnings reports from Addex Therapeutics Ltd, there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.49 for the next earnings report. Addex Therapeutics Ltd’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Addex Therapeutics Ltd is Strong Buy (1), with a target price of $15, which is +1 263.64% compared to the current price. The earnings rating for Addex Therapeutics Ltd stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Addex Therapeutics Ltd has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Addex Therapeutics Ltd has a Sell technical analysis rating based on Technical Indicators (ADX : 58.27, ATR14 : 0.41, CCI20 : -144.95, Chaikin Money Flow : -0.52, MACD : -0.73, Money Flow Index : 9.63, ROC : -69.70, RSI : 21.60, STOCH (14,3) : 1.69, STOCH RSI : 0.02, UO : 22.99, Williams %R : -98.31), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Addex Therapeutics Ltd in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Addex Therapeutics Ltd

Addex Therapeutics Ltd is a biopharmaceutical company. The company operates through single segment which includes developing drugs to improve human health. It is focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. In addition, it is also engaged in the development of the dipraglurant and ADX71441 program. The company's geographical area of operations includes Switzerland and Europe.

CEO: Tim Dyer

Telephone: +41 228841555

Address: Chemin des Aulx 12, Geneva 1228, , CH

Number of employees: 27

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

65%35%

Bearish Bullish

69%31%

Bearish Bullish

63%37%

TipRanks News for ADXN

Wed, 13 Apr 2022 10:25 GMT Addex Therapeutics (ADXN) Gets a Buy Rating from H.C. Wainwright

- TipRanks. All rights reserved.

News

Stocktwits